Biochem/physiol Actions1.4E7 is a hybrid cell line formed by the electrofusion of a primary culture of human pancreatic islets with PANC-1, a human pancreatic ductal carcinoma cell line (ECACC catalogue number 87092802). 1.4E7 has been shown to be tumourigenic when transplanted into a SCID mouse host. The cell line has applications in the study of pancreatic cell biology. 1.4E7 cells provide a method of producing pure insulin secreting cells when stimulated. This is an alternative to the use of primary tissue in cell transplantation therapies for type 1 diabetes. The Y chromosome could not be detected in this cell line by short tandem repeat (STR)-PCR analysis when tested at ECACC. It is a known phenomenon that due to the increased genetic instability of cancer cell lines the Y chromosome can be rearranged or lost resulting in lack of detection. The cell line is identical to the source provided by the depositor based on the STR-PCR analysis.
STR-PCR Data:
Amelogenin: X
CSF1PO: 10,12
D13S317: 11
D16S539: 11
D5S818: 11,13
D7S820: 8
THO1: 7,8
TPOX: 8,11
vWA: 15
Preparation NoteRPMI-1640 + 2 mM Glutamine + 10% FCS / FBS
Split sub-confluent cultures (70-80%) 1:2 to 1:6 , i.e., seeding at 2-4 x 10⁴ cells/cm² using 0.05% trypsin or trypsin/EDTA; 5% CO₂; 37 °C. Population doubling approx 26hrs. At confluence 10⁵ cells/cm² can be expected.
Other NotesAdditional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). Use of this product by commercial organizations may require a license agreement. Commercial customers will be contacted by
[email protected] to provide further information after the order request is submitted. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to
[email protected].
Legal InformationFlatt P & McClenaghan N (2004) Insulin producing cell-line US patent number 20040005702 (A1). Also WO0210346 (A2).
DisclaimerThis cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.
